Pattern’s Ovarian Cancer Combination Candidate Shows Promising In Vivo Results
2024年7月31日 - 6:13AM
Pattern Computer®, Inc. (“Pattern” or “the Company”) announced
today that its ovarian cancer combination candidate has
demonstrated promising synergy and efficacy in an in vivo study
against human ovarian cancer xenografts in mouse models. This
follows initial potential synergy observed in in vitro studies
conducted at a leading global clinical research organization.
Pattern’s combination drug targets high-grade
serous ovarian cancer (HGSOC), the most common and deadliest form
of gynecologic cancer. Despite extensive efforts over the last
three decades, HGSOC still has a 10-year survival rate of less than
30%. This cancer is highly heterogeneous, with a high rate of
relapse and progression, often diagnosed at advanced stages after
spreading to multiple sites. Approximately 80% of patients relapse
despite initial responses to surgery and chemotherapy, and many
develop treatment-resistant disease. Thus, developing targeted drug
combinations that disrupt multiple modes of cancer progression is
of increasing importance.
Combination therapy is a promising strategy for
effectively treating cancer due to its improved efficacy and
reduced toxicity. However, the large number of possible
combinations makes screening for synergistic drug pairs laborious
and expensive. Pattern has developed a cutting-edge computational
platform called the Pattern Discovery Engine™ (PDE). This platform
identifies therapeutically exploitable gene interactions, enabling
the rapid identification and development of synergistic drug
combinations against multifactorial diseases, such as cancer and
diabetes among others.
Mark Anderson, Chair and CEO of Pattern, stated,
“This important discovery underscores the potential of our PDE to
uncover novel therapeutic combinations for hard-to-treat cancers
like HGSOC. We are committed to pushing the boundaries of cancer
treatment through our advanced computational approaches and
bringing hope to patients with few other options. This promising
result is just the beginning, and we are confident in our ability
to make more such discoveries across various types of challenging
cancers. As we work towards transforming cancer treatment
paradigms, we are looking to partner with firms to bring our
combination cancer drug discoveries and diagnostic advances against
the world’s top five cancers into clinical trials.”
About PatternPattern Computer,
Inc. uses its Pattern Discovery Engine™ to solve the most important
and intractable problems in business and medicine. These
proprietary mathematical techniques in advanced AI can find complex
patterns in very-high-order data that have eluded detection by much
larger systems. As the Company applies its computational platform
to the challenging fields of drug discovery and diagnostics, it is
also making major Pattern Discoveries for partners in other
sectors, including extended biotech, materials science, aerospace
manufacturing quality control, veterinary medicine, air traffic
operations, and energy services. See www.patterncomputer.com.
CONTACT: Laura
Guerrant-Oiye (808) 960-2642 – laura@patterncomputer.com
The foregoing contains statements about Pattern
Computer’s future that are not statements of historical fact. These
statements are “forward looking statements” for purposes of
applicable securities laws and are based on current information
and/or management’s good faith belief as to future events. The
words “believe,” “expect,” “anticipate,” “project,” “should,”
“could,” “will,” and similar expressions signify forward-looking
statements. Forward-looking statements should not be read as a
guarantee of future performance. By their nature, forward-looking
statements involve inherent risk and uncertainties, which change
over time, and actual performance could differ materially from that
anticipated by any forward-looking statements. Pattern Computer
undertakes no obligation to update or revise any forward-looking
statement.
Copyright © 2024 Pattern Computer Inc. All
Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine,
PatternBio, TrueXAI, and ProSpectral are trademarks of Pattern
Computer Inc. or its subsidiaries. Other trademarks may be
trademarks of their respective owners.